Isotretinoin therapy for acne: results of a multicenter dose-response study - PubMed (original) (raw)
Clinical Trial
Isotretinoin therapy for acne: results of a multicenter dose-response study
J S Strauss et al. J Am Acad Dermatol. 1984 Mar.
Abstract
One hundred fifty patients with treatment-resistant nodulocystic acne were entered into a double-blind clinical study. Three different dosing levels (0.1, 0.5, 1.0 mg/kg/day) were used in equal-sized groups. In addition to the clinical response, the clinical side effects, the laboratory abnormalities, and the duration of the induced remissions were evaluated with each dose of the drug. There was a highly significant clinical response to treatment with all three dosages of isotretinoin. There was no significant difference in the clinical response between dosages. However, 42% of the patients who received 0.1 mg/kg/day of isotretinoin required retreatment with the drug. This finding, coupled with only minor differences in the clinical side effects and the laboratory abnormalities, indicates that higher dose levels of isotretinoin are indicated for treatment of nodulocystic acne.
Similar articles
- A dose-response study of I3-cis-retinoic acid in acne vulgaris.
Jones DH, King K, Miller AJ, Cunliffe WJ. Jones DH, et al. Br J Dermatol. 1983 Mar;108(3):333-43. doi: 10.1111/j.1365-2133.1983.tb03973.x. Br J Dermatol. 1983. PMID: 6219690 Clinical Trial. - Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion.
Goldstein JA, Socha-Szott A, Thomsen RJ, Pochi PE, Shalita AR, Strauss JS. Goldstein JA, et al. J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):760-5. doi: 10.1016/s0190-9622(82)70066-0. J Am Acad Dermatol. 1982. PMID: 6461679 Clinical Trial. - Isotretinoin and tetracycline in the management of severe nodulocystic acne.
Lester RS, Schachter GD, Light MJ. Lester RS, et al. Int J Dermatol. 1985 May;24(4):252-7. doi: 10.1111/j.1365-4362.1985.tb05775.x. Int J Dermatol. 1985. PMID: 3159698 Clinical Trial. - Isotretinoin treatment of acne and related disorders: an update.
Shalita AR, Cunningham WJ, Leyden JJ, Pochi PE, Strauss JS. Shalita AR, et al. J Am Acad Dermatol. 1983 Oct;9(4):629-38. doi: 10.1016/s0190-9622(83)70176-3. J Am Acad Dermatol. 1983. PMID: 6226726 Review. - Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders.
Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Ward A, et al. Drugs. 1984 Jul;28(1):6-37. doi: 10.2165/00003495-198428010-00002. Drugs. 1984. PMID: 6235105 Review.
Cited by
- Is less more with isotretinoin and acne?
Brar G, Grewal P, Korownyk C. Brar G, et al. Can Fam Physician. 2016 May;62(5):409. Epub 2016 May 12. Can Fam Physician. 2016. PMID: 27255624 Free PMC article. No abstract available. - Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases.
Larsen FG, Nielsen-Kudsk F, Jakobsen P, Weismann K, Kragballe K. Larsen FG, et al. Clin Pharmacokinet. 1992 Jul;23(1):42-61. doi: 10.2165/00003088-199223010-00004. Clin Pharmacokinet. 1992. PMID: 1617858 Review. - What is the best approach to reducing birth defects associated with isotretinoin?
Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. Abroms L, et al. PLoS Med. 2006 Nov;3(11):e483. doi: 10.1371/journal.pmed.0030483. PLoS Med. 2006. PMID: 17121451 Free PMC article. Review. - [Drug therapy of acne].
Ochsendorf FR, Degitz K. Ochsendorf FR, et al. Hautarzt. 2008 Jul;59(7):579-89; quiz 590. doi: 10.1007/s00105-008-1498-y. Hautarzt. 2008. PMID: 18535811 Review. German. - Adverse reactions to oral retinoids. An update.
Mills CM, Marks R. Mills CM, et al. Drug Saf. 1993 Oct;9(4):280-90. doi: 10.2165/00002018-199309040-00006. Drug Saf. 1993. PMID: 8260121 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical